- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Robert Gabbay Discusses How Kerendia's Recommended Drug Status Could Impact Patients With CKD, Diabetes
Robert Gabbay, MD, PhD, of the American Diabetes Association (ADA), talks about the impact that finerenone could have on patients with kidney disease and diabetes.
Robert Gabbay, MD, PhD, of the American Diabetes Association (ADA), talks about the impact that finerenone, a drug that was added to the ADA's list of recommended drugs for chronic kidney disease (CKD) management, could have on patients with CKD and diabetes.
Transcript
What impact do you think adding Kerendia (finerenone) as a recommended medication for the CKD and diabetes populations will have on patient experience?
We're driven by improving the lives of people affected by diabetes. And so, the underlying reason for doing this standards of care is really to help guide clinicians in the best care of their patients. And finerenone is a new treatment that can significantly improve outcomes for people with diabetes. Our hope is that these standards helped to bring the attention to clinicians about this new treatment option.
Weight Fluctuation Threatens Kidney Health in Type 1 Diabetes
February 4th 2025Chronic kidney disease has been linked to yo-yo dieting (also known as body-weight cycling) in the general population, which interested investigators in potential links between these weight fluctuations and increased risk of renal events among a population with type 1 diabetes.
Read More
More Needs to Be Done to Reduce Racial Disparities in Home Dialysis
March 24th 2023On this episode of Managed Care Cast, we speak with Virginia Wang, PhD, and Matthew L. Maciejewski, PhD, who talk about their recent study on racial disparities in home dialysis, and what more needs to be done to increase uptake and reduce disparities in home dialysis for non-White patients.
Listen
Transforming Kidney Care: Policy, Risk Stratification, and Collaborative Models
December 12th 2024Experts at a recent Institute for Value-Based Medicine event emphasized the importance of early intervention, policy innovation, and proactive collaboration to transform the management of kidney disease and optimize patient outcomes.
Read More
